Not yet recruitingPhase 2NCT07208760
L9LS-R21 Interaction
Studying Malaria
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- Bickey H Chang, MD, MHALIG/NIAID/NIH
- Intervention
- Single dose of 1800 mg L9LS SC (12mL)(drug)
- Enrollment
- 357 target
- Eligibility
- 50 years · All sexes
- Timeline
- 2026 – 2029
Study locations (1)
- Sotuba Malaria Research and Training Center (MRTC), Sotouba, Mali
Collaborators
National Institutes of Health (NIH) · Malaria Research and Training Center (MRTC) · Faculté de Médecine Pharmacie d'Odontostomatologie (FMOS) · University of Sciences, Techniques, and Technologies of Bamako (USTTB) · University of Washington · Indiana University School of Medicine, Indiana University
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07208760 on ClinicalTrials.govOther trials for Malaria
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07257965Clinical Study to Assess Minimum Mosquito Bites for P. Vivax Infection in Thai AdultsUniversity of Oxford
- RECRUITINGPHASE2NCT07147400Pfs230D1 + R21 in Matrix-M1 in African School Children and AdultsSerum Institute of India Pvt. Ltd.
- RECRUITINGPHASE2NCT07036159A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 MonthsGlaxoSmithKline
- ACTIVE NOT RECRUITINGPHASE1NCT06735209First-in-Human PfSPZ-LARC2 Vaccination/CHMINational Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGPHASE2NCT07060508L9LS in Women of Childbearing Potential in MaliNational Institute of Allergy and Infectious Diseases (NIAID)
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06549257Assessing the Safety, Immunogenicity and Ex-vivo Efficacy of Two Candidate Malaria Transmission Blocking Vaccines, Pfs25-IMX313 and Pfs45/48 Administered Alone and in Combination, in Matrix-M AdjuvantUniversity of Oxford
- ACTIVE NOT RECRUITINGNANCT06599593Leveraging the Seasonal Malaria Chemoprevention Platform to Address Malaria and MalnutritionUniversity of California, San Francisco
- RECRUITINGPHASE4NCT07038837Comparison of Two Strategies for Administering the R21-Matrix M Vaccine in a Context of Seasonal Malaria Transmission in ChadEpicentre